查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2105705

全球胜肽和寡核苷酸CDMO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Peptide And Oligonucleotide CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 234 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球胜肽和寡核苷酸CDMO市場預計將從2025年的30.4億美元成長至2034年的79.2億美元，2026年至2034年的複合年成長率（CAGR）為11.23%。這個市場快速成長的原因在於，越來越多的製藥和生技公司將基於胜肽和寡核苷酸療法的開發和生產外包給CDMO。 CDMO透過提供專業知識、先進的生產技術和法規遵循支持，幫助製藥公司加速臨床研究、開發和商業化進程。精準醫療投資的增加、RNA療法研發管線的擴展以及對複雜生物製藥日益成長的需求，都在推動市場擴張。核酸療法的持續創新也進一步促進了產業成長。

合約研發生產機構（CDMO）正投資於先進的合成技術、自動化生產系統和高品質的分析能力，以滿足不斷變化的客戶需求。隨著生技公司與契約製造製造商之間合作的深入，生產效率不斷提高，研發週期也正在縮短。對個人化醫療、基因療法和罕見疾病治療日益成長的需求，為專業生產供應商創造了巨大的商機。在法規遵循和可擴展的生產能力方面擁有專業知識，仍然是該行業的關鍵競爭優勢。

隨著基因療法和標靶治療在全球範圍內的持續發展，前景十分光明。製程最佳化、連續生產以及人工智慧驅動的純化技術將進一步提升生產效率和產品品質。臨床研發管線的拓展、製藥業外包業務的增加以及醫療保健領域投資的成長將支撐市場的長期發展。透過持續創新，胜肽類和寡核苷酸領域的合約研發生產機構（CDMO）將成為下一代療法研發中不可或缺的合作夥伴。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球胜肽與寡核苷酸CDMO市場：依產品分類

  • 市場分析、洞察與預測
  • 肽CDMO
  • 寡核苷酸CDMO
  • 肽-寡核苷酸複合物（CDMO）

第5章 全球胜肽與寡核苷酸CDMO市場：依應用領域分類

  • 市場分析、洞察與預測
  • 治療
  • 診斷
  • 研究與藥物發現
  • 疫苗
  • 基因編輯

第6章 全球胜肽與寡核苷酸CDMO市場：依服務類型分類

  • 市場分析、洞察與預測
  • 製程開發
  • GMP生產
  • 分析/品管
  • 灌裝、精加工和包裝
  • 監管和CMC支持

第7章 全球胜肽和寡核苷酸CDMO市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 製藥和生物技術公司
  • 學術研究機構
  • 診斷相關企業
  • 基因和細胞療法開發公司
  • 其他

第8章 全球胜肽和寡核苷酸CDMO市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Bachem
    • PolyPeptide Group
    • Thermo Fisher（Patheon）
    • Catalent
    • Merck KGaA
    • WuXi AppTec/STA
    • Lonza
    • Ajinomoto Bio-Pharma
    • Asymchem
    • Siegfried AG
    • CordenPharma
    • Eurogentec
    • GenScript
    • Almac Group
    • Integrated DNA Tech
    • Agilent
    • Eurofins Genomics
    • Senn Chemicals
    • Rentschler Biopharma
    • Novasep
    • Samsung Biologics
    • Enzene Biosciences
    • PharmaEssentia CDMO
    • Biosynth
    • AmideBio
簡介目錄
Product Code: VMR112119249

The global peptide and oligonucleotide CDMO market size is expected to reach USD 7.92 Billion in 2034 from USD 3.04 Billion in 2025, growing at a CAGR of 11.23 during 2026-2034.This market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of peptide- and oligonucleotide-based therapeutics. Contract development and manufacturing organizations provide specialized expertise, advanced production technologies, and regulatory support, enabling drug developers to accelerate clinical research and commercialization. Rising investments in precision medicine, expanding pipelines of RNA-based therapies, and increasing demand for complex biologics are driving market expansion. Continuous innovation in nucleic acid therapeutics is further strengthening industry growth.

CDMOs are investing in advanced synthesis technologies, automated manufacturing systems, and high-quality analytical capabilities to meet growing customer requirements. Increasing collaboration between biotechnology companies and contract manufacturers is improving production efficiency while reducing development timelines. Growing demand for personalized medicines, gene therapies, and rare disease treatments is creating substantial opportunities for specialized manufacturing providers. Regulatory compliance expertise and scalable manufacturing capacity remain key competitive advantages within the industry.

The future outlook remains highly promising as genetic medicine and targeted therapeutics continue advancing worldwide. Artificial intelligence-assisted process optimization, continuous manufacturing, and improved purification technologies will enhance production efficiency and product quality. Expanding clinical pipelines, increasing pharmaceutical outsourcing, and rising healthcare investments will support long-term market growth. Continuous innovation will establish peptide and oligonucleotide CDMOs as critical partners in the development of next-generation therapeutics.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

  • Peptide CDMO
  • Oligonucleotide CDMO
  • Peptide-Oligonucleotide Conjugate CDMO

By Application

  • Therapeutics
  • Diagnostics
  • Research & Discovery
  • Vaccines
  • Gene Editing

By Service Type

  • Process Development
  • GMP Manufacturing
  • Analytical & Quality Control
  • Fill-Finish & Packaging
  • Regulatory & CMC Support

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Diagnostic Companies
  • Gene & Cell Therapy Developers
  • Others

COMPANIES PROFILED

  • Bachem, PolyPeptide Group, Thermo Fisher (Patheon), Catalent, Merck KGaA, WuXi AppTec/STA, Lonza, Ajinomoto Bio-Pharma, Asymchem, Siegfried AG, CordenPharma, Eurogentec, GenScript, Almac Group, Integrated DNA Tech, Agilent, Eurofins Genomics, Senn Chemicals, Rentschler Biopharma, Novasep, Samsung Biologics, Enzene Biosciences, PharmaEssentia CDMO, Biosynth, AmideBio

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Peptide CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Oligonucleotide CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Peptide-Oligonucleotide Conjugate CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Research & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Gene Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Service Type
  • 6.2. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. GMP Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Analytical & Quality Control Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Fill-Finish & Packaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Regulatory & CMC Support Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY END USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End User
  • 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Gene & Cell Therapy Developers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Product
    • 8.2.2 By Application
    • 8.2.3 By Service Type
    • 8.2.4 By End User
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Product
    • 8.3.2 By Application
    • 8.3.3 By Service Type
    • 8.3.4 By End User
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Product
    • 8.4.2 By Application
    • 8.4.3 By Service Type
    • 8.4.4 By End User
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Product
    • 8.5.2 By Application
    • 8.5.3 By Service Type
    • 8.5.4 By End User
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Product
    • 8.6.2 By Application
    • 8.6.3 By Service Type
    • 8.6.4 By End User
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Bachem
    • 10.2.2 PolyPeptide Group
    • 10.2.3 Thermo Fisher (Patheon)
    • 10.2.4 Catalent
    • 10.2.5 Merck KGaA
    • 10.2.6 WuXi AppTec/STA
    • 10.2.7 Lonza
    • 10.2.8 Ajinomoto Bio-Pharma
    • 10.2.9 Asymchem
    • 10.2.10 Siegfried AG
    • 10.2.11 CordenPharma
    • 10.2.12 Eurogentec
    • 10.2.13 GenScript
    • 10.2.14 Almac Group
    • 10.2.15 Integrated DNA Tech
    • 10.2.16 Agilent
    • 10.2.17 Eurofins Genomics
    • 10.2.18 Senn Chemicals
    • 10.2.19 Rentschler Biopharma
    • 10.2.20 Novasep
    • 10.2.21 Samsung Biologics
    • 10.2.22 Enzene Biosciences
    • 10.2.23 PharmaEssentia CDMO
    • 10.2.24 Biosynth
    • 10.2.25 AmideBio